H
Heinrike Schmeling
Researcher at Alberta Children's Hospital
Publications - 64
Citations - 2450
Heinrike Schmeling is an academic researcher from Alberta Children's Hospital. The author has contributed to research in topics: Arthritis & Medicine. The author has an hindex of 21, co-authored 55 publications receiving 1998 citations. Previous affiliations of Heinrike Schmeling include University of Calgary & Martin Luther University of Halle-Wittenberg.
Papers
More filters
Journal ArticleDOI
The German etanercept registry for treatment of juvenile idiopathic arthritis
Gerd Horneff,Heinrike Schmeling,T Biedermann,Ivan Foeldvari,Gerd Ganser,HJ Girschick,Toni Hospach,Hans Iko Huppertz,R. Keitzer,R. M. Küster,H Michels,D Moebius,B. Rogalski,A. Thon +13 more
TL;DR: Etanercept treatment was safe and led to a significant improvement in most JIA patients resistant to conventional treatment, and lower in patients with systemic onset arthritis.
Journal ArticleDOI
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry
TL;DR: The patients' disease activity improved during etanercept monotherapy and etanorcept and methotrexate combination therapy and Tolerability in both treatment groups was comparable.
Journal ArticleDOI
The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort
Jaime Guzman,Kiem Oen,Lori B. Tucker,Adam M. Huber,Natalie J. Shiff,Gilles Boire,Rosie Scuccimarri,Roberta A. Berard,Shirley M. L. Tse,Kimberly Morishita,Elizabeth Stringer,Nicole Johnson,Deborah M. Levy,Karen Watanabe Duffy,David A. Cabral,Rosenberg Am,Maggie Larché,Paul Dancey,Ross E. Petty,Ronald M. Laxer,Earl D. Silverman,Paivi Miettunen,Anne-Laure Chetaille,Elie Haddad,Kristin Houghton,Lynn Spiegel,Stuart E. Turvey,Heinrike Schmeling,Bianca Lang,Janet Ellsworth,Suzanne E. Ramsey,Alessandra Bruns,Sarah Campillo,Susanne M. Benseler,Gaëlle Chédeville,Rayfel Schneider,Rae S. M. Yeung,Ciarán M. Duffy +37 more
TL;DR: Most children with JIA managed with contemporary treatments attain inactive disease within 2 years of diagnosis and many are able to discontinue treatment, except for children with polyarthritis.
Journal ArticleDOI
Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations
Dirk Foell,Helmut Wittkowski,Inga Hammerschmidt,Nico M Wulffraat,Heinrike Schmeling,Michael Frosch,Gerd Horneff,W. Kuis,Clemens Sorg,Johannes Roth +9 more
TL;DR: S100A12 serum concentrations indicate neutrophil activation in JRA and correlate with disease activity, and its function as a proinflammatory factor secreted by activated neutrophils makes this protein a potential target for future therapies.
Journal ArticleDOI
Etanercept and uveitis in patients with juvenile idiopathic arthritis
Heinrike Schmeling,Gerd Horneff +1 more
TL;DR: During treatment with etanercept, there were both relapses and first courses of uveitis, and the frequency and severity ofUveitis seemed not to be influenced by etanerscept, a sign that patients with relapsing Uveitis before institution of etanenercept treatment remain at high risk of the development of uVEitis flares despite etanorcept treatment.